The present invention provides new organic compounds of the following formula: €ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒA-L1-B-C-D-L2-E wherein A, L1, B, C, D, L2 and E are as defined in the description of the invention, that are useful for treating or preventing conditions or disorders associated with DGAT1 activity, particularly type 2 diabetes, and pharmaceutical compositions comprising such compounds.